Aurora kinase inhibitor patents and agents in clinical testing

An update (2011-2013)

Chun-Hei Cheung, Sailu Sarvagalla, Jane Ying Chieh Lee, Yi Chun Huang, Mohane Selvaraj Coumar

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Introduction: Aurora kinase A, B and C, members of serine/threonine kinase family, are key regulators of mitosis. As Aurora kinases are overexpressed in many of the human cancers, small-molecule inhibitors of Aurora kinase have emerged as a possible treatment option for cancer. Areas covered: In 2009 and 2011, the literature pertaining to Aurora kinase inhibitors and their patents was reviewed. Here, the aim is to update the information for Aurora kinase inhibitors in clinical trials and the patents filed between the years 2011 and 2013. Pubmed, Scopus®, Scifinder®, USPTO, EPO and www.clinicaltrials.gov databases were used for searching the literature and patents for Aurora kinase inhibitors. Expert opinion: Even though both Aurora sub-type selective as well as pan-selective inhibitors show preclinical and clinical efficacy, so far no Aurora kinase inhibitor has been approved for clinical use. Particularly, dose-limiting toxicity (neutropenia) is a key issue that needs to be addressed. Preliminary evidence suggests that the use of selective Aurora A inhibitors could avoid Aurora B-mediated neutropenia in clinical settings. Also, use of adjunctive agents such as granulocyte stimulating factor to overcome neutropenia associated with Aurora B inhibition could be an answer to overcome the toxicity and bring Aurora inhibitors to market in the future.

Original languageEnglish
Pages (from-to)1021-1038
Number of pages18
JournalExpert Opinion on Therapeutic Patents
Volume24
Issue number9
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Aurora Kinases
Patents
Neutropenia
Aurora Kinase C
Aurora Kinase B
Aurora Kinase A
Protein-Serine-Threonine Kinases
Expert Testimony
Granulocytes
Mitosis
PubMed
Neoplasms
Clinical Trials
Databases

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

Cheung, Chun-Hei ; Sarvagalla, Sailu ; Lee, Jane Ying Chieh ; Huang, Yi Chun ; Coumar, Mohane Selvaraj. / Aurora kinase inhibitor patents and agents in clinical testing : An update (2011-2013). In: Expert Opinion on Therapeutic Patents. 2014 ; Vol. 24, No. 9. pp. 1021-1038.
@article{b54d29ee36e84dff9ccdb9671dabb8fe,
title = "Aurora kinase inhibitor patents and agents in clinical testing: An update (2011-2013)",
abstract = "Introduction: Aurora kinase A, B and C, members of serine/threonine kinase family, are key regulators of mitosis. As Aurora kinases are overexpressed in many of the human cancers, small-molecule inhibitors of Aurora kinase have emerged as a possible treatment option for cancer. Areas covered: In 2009 and 2011, the literature pertaining to Aurora kinase inhibitors and their patents was reviewed. Here, the aim is to update the information for Aurora kinase inhibitors in clinical trials and the patents filed between the years 2011 and 2013. Pubmed, Scopus{\circledR}, Scifinder{\circledR}, USPTO, EPO and www.clinicaltrials.gov databases were used for searching the literature and patents for Aurora kinase inhibitors. Expert opinion: Even though both Aurora sub-type selective as well as pan-selective inhibitors show preclinical and clinical efficacy, so far no Aurora kinase inhibitor has been approved for clinical use. Particularly, dose-limiting toxicity (neutropenia) is a key issue that needs to be addressed. Preliminary evidence suggests that the use of selective Aurora A inhibitors could avoid Aurora B-mediated neutropenia in clinical settings. Also, use of adjunctive agents such as granulocyte stimulating factor to overcome neutropenia associated with Aurora B inhibition could be an answer to overcome the toxicity and bring Aurora inhibitors to market in the future.",
author = "Chun-Hei Cheung and Sailu Sarvagalla and Lee, {Jane Ying Chieh} and Huang, {Yi Chun} and Coumar, {Mohane Selvaraj}",
year = "2014",
month = "1",
day = "1",
doi = "10.1517/13543776.2014.931374",
language = "English",
volume = "24",
pages = "1021--1038",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "9",

}

Aurora kinase inhibitor patents and agents in clinical testing : An update (2011-2013). / Cheung, Chun-Hei; Sarvagalla, Sailu; Lee, Jane Ying Chieh; Huang, Yi Chun; Coumar, Mohane Selvaraj.

In: Expert Opinion on Therapeutic Patents, Vol. 24, No. 9, 01.01.2014, p. 1021-1038.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Aurora kinase inhibitor patents and agents in clinical testing

T2 - An update (2011-2013)

AU - Cheung, Chun-Hei

AU - Sarvagalla, Sailu

AU - Lee, Jane Ying Chieh

AU - Huang, Yi Chun

AU - Coumar, Mohane Selvaraj

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Introduction: Aurora kinase A, B and C, members of serine/threonine kinase family, are key regulators of mitosis. As Aurora kinases are overexpressed in many of the human cancers, small-molecule inhibitors of Aurora kinase have emerged as a possible treatment option for cancer. Areas covered: In 2009 and 2011, the literature pertaining to Aurora kinase inhibitors and their patents was reviewed. Here, the aim is to update the information for Aurora kinase inhibitors in clinical trials and the patents filed between the years 2011 and 2013. Pubmed, Scopus®, Scifinder®, USPTO, EPO and www.clinicaltrials.gov databases were used for searching the literature and patents for Aurora kinase inhibitors. Expert opinion: Even though both Aurora sub-type selective as well as pan-selective inhibitors show preclinical and clinical efficacy, so far no Aurora kinase inhibitor has been approved for clinical use. Particularly, dose-limiting toxicity (neutropenia) is a key issue that needs to be addressed. Preliminary evidence suggests that the use of selective Aurora A inhibitors could avoid Aurora B-mediated neutropenia in clinical settings. Also, use of adjunctive agents such as granulocyte stimulating factor to overcome neutropenia associated with Aurora B inhibition could be an answer to overcome the toxicity and bring Aurora inhibitors to market in the future.

AB - Introduction: Aurora kinase A, B and C, members of serine/threonine kinase family, are key regulators of mitosis. As Aurora kinases are overexpressed in many of the human cancers, small-molecule inhibitors of Aurora kinase have emerged as a possible treatment option for cancer. Areas covered: In 2009 and 2011, the literature pertaining to Aurora kinase inhibitors and their patents was reviewed. Here, the aim is to update the information for Aurora kinase inhibitors in clinical trials and the patents filed between the years 2011 and 2013. Pubmed, Scopus®, Scifinder®, USPTO, EPO and www.clinicaltrials.gov databases were used for searching the literature and patents for Aurora kinase inhibitors. Expert opinion: Even though both Aurora sub-type selective as well as pan-selective inhibitors show preclinical and clinical efficacy, so far no Aurora kinase inhibitor has been approved for clinical use. Particularly, dose-limiting toxicity (neutropenia) is a key issue that needs to be addressed. Preliminary evidence suggests that the use of selective Aurora A inhibitors could avoid Aurora B-mediated neutropenia in clinical settings. Also, use of adjunctive agents such as granulocyte stimulating factor to overcome neutropenia associated with Aurora B inhibition could be an answer to overcome the toxicity and bring Aurora inhibitors to market in the future.

UR - http://www.scopus.com/inward/record.url?scp=84906223147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906223147&partnerID=8YFLogxK

U2 - 10.1517/13543776.2014.931374

DO - 10.1517/13543776.2014.931374

M3 - Review article

VL - 24

SP - 1021

EP - 1038

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 9

ER -